Monday, July 20, 2015
In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable. The results appeared in a study published online today in Nature Medicine.
Patients received an infusion of altered immune cells known as T-cells roughly 2.4 billion of them after undergoing a stem cell transplantation of their own stem cells. In 16 of 20 patients with advanced disease, there was a significant clinical response. The scientists found that the T-cell therapy was generally well-tolerated and that modified immune cells traveled to the bone marrow, where myeloma tumors typically are found, and showed a long-term ability to fight the tumors. Relapse was generally associated with a loss of the engineered T-cells.
This study suggests that treatment with engineered T-cells is not only safe but of potential clinical benefit to patients with certain types of aggressive multiple myeloma, says first author Aaron P. Rapoport, MD, the Gary Jobson Professor in Medical Oncology at the University of Maryland School of Medicine. Our findings provide a strong foundation for further research in the field of cellular immunotherapy for myeloma to help achieve even better results for our patients.
The trial is the first published use of genetically modified T-cells for treating patients with multiple myeloma. The approach has been used to treat leukemia as well as lymphoma, according to Dr. Rapoport, who is the Director of the Blood and Marrow Transplant Program at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.
More than 77,000 people in the United States have multiple myeloma, with about 24,000 new cases diagnosed each year. Patients are treated with chemotherapy and in many cases an autologous stem cell transplant, but long-term response rates are low, and median survival is three to five years.
The majority of patients who participated in this trial had a meaningful degree of clinical benefit, Dr. Rapoport notes. Even patients who later relapsed after achieving a complete response to treatment or didnt have a complete response had periods of disease control that I believe they would not have otherwise experienced. Some patients are still in remission after nearly three years.
The research is a collaboration between the University of Maryland School of Medicine, the Perelman School of Medicine at the University of Pennsylvania and Adaptimmune, a clinical stage biopharmaceutical company which owns the core T-cell receptor technology and funded the study. Dr. Rapoport and co-authors Edward A. Stadtmauer, MD, of the University of Pennsylvania Abramson Cancer Center, and Gwendolyn K. Binder-Scholl, PhD, of Adaptimmune, contributed equally to the research. Dr. Rapoport is the studys principal investigator.
In the clinical study, patients T-cells were engineered to express an affinity-enhanced T-cell receptor (TCR) specific for a type of tumor antigen, or protein, known as a cancer-testis antigen (CT antigen). The target CT antigens were NY-ESO-1 and LAGE-1. Up to 60 percent of advanced myelomas have been reported to express NY-ESO-1 and/or LAGE-1, which correlates to tumor proliferation and poorer outcomes. According to Adaptimmune, the trial is the first published study of lentiviral vector mediated TCR gene expression in humans.
Of the 20 patients treated, 14 (70 percent) had a near complete or complete response three months after treatment. Median progression-free survival was 19.1 months and overall survival was 32.1 months. Two patients had a very good partial response three months post treatment. Half the patients were treated at the University of Maryland Greenebaum Cancer Center and half at the University of Pennsylvania Abramson Cancer Center. Researchers note that the response rate was better than would be expected for a standard autologous stem cell transplant. In addition, patients did not experience side effects which have been associated with another type of genetically engineered T-cells (chimeric antigen receptors, or CARS) used to treat other cancers.
The study was originally developed by Carl H. June, MD, of the University of Pennsylvania Abramson Cancer Center, and Dr. Rapoport, who have been research collaborators for 18 years.
Multiple myeloma is a treatable but largely incurable cancer. This study reveals the promise that immunotherapy with genetically engineered T-cells holds for boosting the bodys ability to attack the cancer and provide patients with better treatments and control of their disease, says E. Albert Reece, MD., PhD, MBA, vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and dean of the University of Maryland School of Medicine. This trial is also an excellent example of significant scientific advances that result from collaborations between academic medical institutions and private industry.
The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States. It continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Marylands Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global presence, with research and treatment facilities in more than 35 countries around the world. medschool.umaryland.edu/
The University of Maryland Marlene and Stewart Greenebaum Cancer Center, a National Cancer Institute-designated center in Baltimore affiliated with the University of Maryland Medical Center and University of Maryland School of Medicine, offers a multidisciplinary approach to treating all types of cancer and has an active cancer research program. It is ranked in the top 50 cancer programs in the nation by U.S. News & World Report. http://www.umgcc.org.
Go here to read the rest:
Patients' Own Genetically Altered Immune Cells Show ...
- Pluristyx, panCELLa, and Implant Therapeutics Announce Definitive Merger Agreement - Business Wire - October 13th, 2022
- Johns Hopkins Scientists Have Developed a Nanobody That May Treat Parkinson's Disease - SciTechDaily - September 25th, 2022
- UMD students contribute to tech, health fields with summer research projects - The Diamondback - September 16th, 2022
- Pair of Hopkins teams receive $200K in technology grants - Maryland Daily Record - August 22nd, 2022
- RoosterBio and AGC Biologics team up to accelerate manufacture of cell and exosome therapies - BioPharma-Reporter.com - August 22nd, 2022
- Stem Cell Transplant Reverses Sickle Cell Disease in Adults - July 3rd, 2022
- LONGEVERON INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - May 15th, 2022
- Top Ways To Rejuvenate Your Body And Improve Your Well-being - The Southern Maryland Chronicle - April 19th, 2022
- BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress... - April 19th, 2022
- Synthetic biology's past, present and future explored in timely new account - Winnipeg Free Press - April 6th, 2022
- US is Out of Step on Primate Research With Rest of World - NewsClick - October 5th, 2021
- A Look Inside A Termite's Gut Wins The 11th Annual Nikon Small World in Motion Competition - PRNewswire - August 18th, 2021
- What really happened in Wuhan? - The Sunday Guardian Live - The Sunday Guardian - June 6th, 2021
- UMD Researchers Perform Crucial Proof-of-Concept ... - December 20th, 2020
- US gets more help in raging battle against COVID-19 as FDA authorizes Moderna vaccine, the second allowed for emergency use - USA TODAY - December 20th, 2020
- Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer | DNA RNA and Cells | News Channels -... - December 7th, 2020
- Trump was one of the first 10 patients to get an experimental COVID-19 treatment under special use - Yahoo News - October 8th, 2020
- New toilet, a VR camera and science experiments are heading to t - KAKE - October 8th, 2020
- ShoreRivers awarded DNR grant for two restoration projects - MyEasternShoreMD - August 26th, 2020
- CRISPR cows could boost sustainable meat production, but regulations and wary consumers stand in the way - Genetic Literacy Project - August 26th, 2020
- Over $8M in 2020 Stem Cell Funding Awards Continue to Fuel Marylands Leading Cell Therapy Industry - BioBuzz - June 24th, 2020
- Researchers develop nanoengineered bioink to 3D print functional bone tissue - 3D Printing Industry - May 27th, 2020
- 'Virus Goes In, Virus Goes Out': Advocates Call For Release Of More Low-Level Prisoners To Stem Infection Rate - Kaiser Health News - May 22nd, 2020
- What Do New Neurons in the Brains of Adults Actually Do? - The Scientist - May 7th, 2020
- David C. Karli is Offering a New Ray of Hope Through Regenerative Medicine - RESPECT. - May 3rd, 2020
- Could Innate Immunology Save Us From the Coronavirus? - The New York Times - May 3rd, 2020
- Watch: Hogan orders closure of bars, restaurants, theaters and gyms, restricts gatherings - Maryland Daily Record - March 22nd, 2020
- Dr Borehams Crucible: The small cap biotechs trying to make a buck from coronavirus - Stockhead - March 9th, 2020
- The Aussie Biotech Companies Trying To Make A Buck From Coronavirus - D'Marge - March 9th, 2020
- Organoids, iPSCs, and advanced cell models: Advancing discovery from basic research to drug discovery - Science Magazine - March 4th, 2020
- Maryland Stem Cell Center Consortium & Core Facility ... - March 4th, 2020
- Serving those who serve - The Hub at Johns Hopkins - November 14th, 2019
- BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic... - November 6th, 2019
- VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen - PR Web - November 6th, 2019
- Contrasting of Applied Therapeutics Inc. (APLT) and Neuralstem Inc. (NASDAQ:CUR) - MS Wkly - November 6th, 2019
- Reviewing Synthetic Biologics Inc. (SYN)'s and Asterias Biotherapeutics Inc. (:)'s results - FinanceMercury - November 6th, 2019
- Comparing of Neuralstem Inc. (CUR) and Allakos Inc. (NASDAQ:ALLK) - MS Wkly - November 6th, 2019
- Head-To-Head Survey: Intrexon (NASDAQ:XON) versus US Stem Cell (NASDAQ:USRM) - Riverton Roll - September 25th, 2019
- Analyzing US Stem Cell (OTCMKTS:USRM) and Intrexon (OTCMKTS:XON) - TechNewsObserver - September 25th, 2019
- Reviewing Intrexon (NASDAQ:XON) & US Stem Cell (NASDAQ:USRM) - Mayfield Recorder - September 25th, 2019
- Artificially Engineering Intestine - Mirage News - September 25th, 2019
- Prothena Corporation plc (PRTA)'s Financial Results Comparing With Neuralstem Inc. (NASDAQ:CUR) - The EN Herald - September 25th, 2019
- cord_blood - Maryland - September 14th, 2019
- Stem Cells and Type 1 Diabetes: What the Future Has in ... - April 24th, 2019
- Stem Cell Therapy in Maryland | Stem Cell Professionals - April 5th, 2019
- Meristem - Wikipedia - January 17th, 2019
- Stem Cell Therapy in Annapolis Maryland | Stem Cell ... - October 25th, 2018
- Stem Cell Centers - Towson > Stem Cell Centers - October 6th, 2018
- STEM CELL THERAPY - Orthopedic and Wellness Maryland - September 5th, 2018
- Patient Resources | University of Maryland School of Medicine - September 5th, 2018
- Stem Cell Clinical Trial | University of Maryland Children ... - August 17th, 2018
- Baltimore, Maryland Stem Cell Transplants, Montgomery ... - August 17th, 2018
- Nervous System Stem Cells Can Replace Themselves, Give ... - July 3rd, 2018
- Excellence in Stem Cell Research | University of Maryland ... - June 24th, 2018
- Maryland Stem Cell Research Fund: 2014 Awardees - June 24th, 2018
- Catholic response to stem cells - Featured Today ... - October 14th, 2017
- Free stem cell Essays and Papers - 123HelpMe - October 12th, 2017
- How Stem Cell Therapy Can Help Repair and Regenerate Your Body - October 12th, 2017
- How Stem Cell Therapy Can Help Repair and ... - Mercola.com - September 4th, 2017
- Science and technology to get boost from CRS-12 mission - SpaceFlight Insider - August 12th, 2017
- Cannon Scholars visit National Institute of Standards and Technology - Dover Post - August 9th, 2017
- Lab-Grown, Virus-Free Stem Cells Repair Retinal Tissue in ... - August 9th, 2017
- Roanoke researchers pursue treatments for the type of deadly brain cancer affecting McCain - Roanoke Times - August 3rd, 2017
- The Maryland Stem Cell Research Fund (MSCRF) | Tedco - November 25th, 2016
- Center for Stem Cell Biology & Regenerative Medicine ... - November 14th, 2016
- Ginger | University of Maryland Medical Center - September 6th, 2016
- Johns Hopkins Team Creates Stem Cells From Schizophrenia ... - September 5th, 2016
- Human Induced Pluripotent Stem Cell Derived Neuronal Cells ... - August 18th, 2016
- Maryland Stem Cell Center Consortium and Core Facility ... - August 12th, 2016
- Human Stem Cells Institute - Wikipedia, the free encyclopedia - October 19th, 2015
- Maryland Stem Cell Research Fund: Funding Opportunities - July 2nd, 2015
- MRI based on a sugar molecule can tell cancerous from noncancerous cells - March 27th, 2015
- MD Stem Cells Release Optic Nerve Vision Loss Reversed ... - March 22nd, 2015
- TiGenix: TiGenix reports its full year 2014 results - March 18th, 2015
- Gene regulatory path revealed as target for therapy of aggressive pediatric brain cancer - March 10th, 2015
- American Spine offers experimental fix for pain -- Gazette.Net - January 28th, 2015
- American Spine offers experimental fix for pain - January 28th, 2015
- Toughest Breast Cancer May Have Met Its Match - December 9th, 2014
- Bid on Stem Cells and Alcohol-induced Tissue Injuries (R21 ... - November 12th, 2014
- Head, National Institutes of Health Stem Cell Technology ... - November 11th, 2014